IN THE NEWS
The UM BioPark is a Beacon for Early-Stage Technology Ventures
The research park’s perfectly matched location and array of startup-supporting resources makes it an invaluable pillar for a growing number of life science startups — and the entire Maryland ecosystem.
The Commons Podcast Season 4, Episode 2: Beautiful Cells: A Conversation with Elaine Haynes CEO of KaloCyte
Host, Thomas Osha sits down with KaloCyte’s CEO – Elaine Haynes in the company’s lab at the University of Maryland, Baltimore and UMB BioPark to discuss their groundbreaking bio-inspired artificial red blood cells and what’s next for this very interesting start-up.
TEDCO Invests SSBCI Funding into Kalocyte, Inc.
TEDCO, Maryland’s economic engine for technology companies, announced a recent $500,000 State Small Business Credit Initiative (SSBCI) investment into KaloCyte, Inc. This investment came through TEDCO’s Venture Funds.
Governor Moore Focuses on Jobs, Economy in Fifth Bill Signing
Moore compared the bill to public sector grant funding that went to companies such as KaloCyte. The Baltimore-based company is working to develop an artificial red blood cell substitute product. Moore spoke about
the company and Elaine Haynes, president and CEO of the company, during his pre-bill signing remarks.
Penn State Scientist Plays Key Role in $46M Artificial Blood Research Program
Penn State Professor Dipanjan Pan co-invented ErythroMer, an artificial oxygen carrier, that will be used in a $46 million project led by the University of Maryland School of Medicine to develop an artificial whole blood product.
AABB News: Biosynthetic Components Come Together in Search for Whole Blood Substitutes
Transfusion medicine is dependent upon altruistic blood donors, the time of year, geography, screening and testing time, storage limitations and the logistics of getting blood where it is needed. The next advance — the development of a biosynthetic whole-blood surrogate product with a long shelf life that can be freeze-dried for easy portability, storage and reconstituted on site when needed — is closer than ever before.
Research Explained in 70 Seconds – UMB on Instagram
Imagine being able to carry artificial blood to a wounded soldier in a remote area to save their life. That’s one of the potential benefits of a $46.4 million study to develop and test artificial blood being led by #UMSOM Professor Allan Doctor. @darpa is administering the project. Dozens of universities and biotech companies are also collaborating.
Baltimore’s KaloCyte Partners on $46M DARPA Program to Develop Synthetic Blood Product
“This partnership with DARPA is highly complementary to our work,” Elaine Haynes, President and Chief Executive Officer of KaloCyte said. DARPA will provide $46 million in funding to KaloCyte and the other FSHARP members to support development of the synthetic solution.
The Pittsburgh Post-Gazette: DARPA Puts $46.4M Toward Synthetic Blood Development
The Defense Advanced Research Projects Agency announced it will grant a total of $46.4 million to a number of organizations, including KaloCyte, UMB, and the University of Pittsburgh.
ErythroMer Featured in Drug Discovery News – December 2022/January 2023 Issue
Facing donor shortages and storage limitations, researchers are developing synthetic red blood cells, platelets, and plasma and combining them into artificial blood.
QUICK LINKS
ABOUT US
KaloCyte was founded by a distinguished team of researchers in physiology, bioengineering, and trauma care and is poised to deliver ErythroMer, a dried, bio-inspired artificial red blood cell, to market. ErythroMer is envisioned for use when stored red blood cells are unavailable, undesirable or in short supply. KaloCyte is supported by over $20M in federal grants and investor funding.